Clinical Trials Medtech - September 7, 2016
OssDsign presents preliminary data
Karolinska Development portfolio company OSSDSIGN presented preliminary data at European Congress of Neurosurgery 2016 in Athens, indicating that OSSDSIGN Cranial may provide better, more permanent solution for cranioplasty, even in a complex patient population. OSSDSIGN found, in a retrospective study of patients undergoing cranioplasty using OSSDSIGN Cranial, 96.7% of patients treated showed no signs of post-operative […]
Pharma Business - May 10, 2016
Karolinska Development’s first quarter 2016
Karolinska Development has published its Interim Report for the period January to March 2016. Significant events during Karolinska Development’s first quarter this year include Aprea raising SEK 437 million in a Series B financing round from a syndicate of specialist international life science investors. This was the largest ever completed by a Karolinska Development portfolio company and […]
MedTech Business - February 6, 2016
OssDsign receives CE mark approval
Swedish designer and manufacturer of implants and technology for bone regeneration, OssDsign, has received CE mark approval for its bio-ceramic burr hole plug, Cranioplug. The product Cranioplug will complement OssDsign’s lead products Sculpter Cranial and Sculpter Facial, which are available in Germany, the UK, and the Nordic countries, with further market expansion ongoing. ”This is an […]
Uncategorized - April 3, 2014
OssDsign and Q-linea on top technology list
The two firms are on the prestigious list of Sweden’s 33 most promising technology companies.